STAT reported that the FDA and Eli Lilly approved an April application by a 79-year-old man for experimental retatrutide through the compassionate-use program, with a top NIH clinician submitting the request. Donald Trump, who turned 80, has denied taking the drug. The identity of the applicant remains unconfirmed in public records.
“Is Donald Trump on a Wonder Weight Loss Drug? Here’s What You Need to Know.”
Read at Slate →No center sources covered this
“Trump denies taking super-strength obesity drug - The Telegraph”
Read at The Telegraph →Wealth and political connections allow elites to obtain experimental treatments unavailable to ordinary patients through programs like Medicare.
“Systemic favoritism in healthcare access and lack of transparency from political figures”
Unverified reporting from outlets like STAT and Slate attempts to manufacture doubt about Trump’s fitness without evidence.
“Speculative media scrutiny and preference for personal denial over bureaucratic pharmaceutical reliance”
FDA pre-market rules force even prominent individuals into regulatory exceptions instead of allowing direct medical choice.
“Government gatekeeping that restricts individual liberty and creates selective access”
All perspectives assume a plausible Trump link despite only an age match and no public confirmation of identity or health timeline.
“Evidentiary gap and unexamined regulatory details that undermine both elite-access and bureaucracy critiques”
Ratings by MBFC